Financial Performance - The company's total revenue for the reporting period is approximately CNY 79.77 million, a decrease of 51.67% compared to the previous year[4] - The total profit for the period is a loss of CNY 52.95 million, representing a decline of 436.93% year-on-year[4] - The net profit attributable to shareholders is a loss of CNY 43.39 million, down 399.56% from the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses is a loss of CNY 45.70 million, a decrease of 984.35% year-on-year[4] - Basic earnings per share are reported at -CNY 0.63, a decline of 399.56% compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period amount to CNY 474.93 million, an increase of 3.68% year-on-year[6] - Shareholders' equity attributable to the company is CNY 233.31 million, down 17.60% from the beginning of the period[6] Market Conditions - The decline in revenue and profit is attributed to weak market demand, increased competition, and rising marketing expenses[7] - The company has faced increased asset impairment losses and bad debt provisions due to changes in market conditions[7] Cautionary Notes - The company anticipates that the financial data presented is preliminary and subject to audit, urging investors to be cautious[8]
春光药装(838810) - 2024 Q4 - 年度业绩